Skip to main content

Day: May 2, 2025

Lancaster Appoints Andrew Watson as President & CEO

VANCOUVER, British Columbia, May 02, 2025 (GLOBE NEWSWIRE) — Lancaster Resources Inc. (CSE:LCR | OTC Pink:LANRF | FRA:6UF0) (“Lancaster” or the “Company”) is pleased to announce the appointment of Andrew Watson as its President and Chief Executive Officer, effective May 1, 2025. Highlights:Brings over 23 years of technical and executive leadership in the exploration and development of critical minerals (including uranium and lithium), precious metals (notably gold), and conventional energy. Led the acquisition of all of the Company’s gold projects, including the 100%-owned Piney Lake Gold Project in Saskatchewan and the Lake Cargelligo Gold Project in New South Wales, Australia. Key architect of Lancaster’s strategic positioning in uranium, with 100%-owned projects in the Athabasca Basin, the world’s premier uranium district. Led...

Continue reading

SOPerior Fertilizer Corp. Announced Board and Management Changes

Toronto, Ontario, May 02, 2025 (GLOBE NEWSWIRE) — SOPerior Fertilizer Corp. (TSXV:SOP.H) (the “Company” or “SOPerior“) announces all directors have resigned from the Board, effective April 30, 2025. In addition, all officers have resigned their positions as officers, effective April 30, 2025. The following directors and officers have resigned from the Company:Alan C. Abrams (Director);Arran Thorpe (Director);Andrew Squires (Chief Executive Officer and Director); andOlga Nikitovic (Chief Financial Officer).Negotiations with the proposed JV counterparty have terminated and the Company has no other viable alternatives to continue operations given its significant liabilities and limited cash. The Company was unsuccessful in its bid to reacquire the SITLA Other Business Arrangement for the...

Continue reading

Further information in regards to AS Tallinna Vesi annual ESEF report for 2024

On 25 April 2025, AS Tallinna Vesi published a stock exchange announcement regarding the Supervisory Board’s approval of the audited Annual Report for 2024. Today, the company is additionally publishing the Annual Report for 2024 in ESEF format, together with the independent auditor’s report. More information: Taavi GröönChief Financial OfficerAS Tallinna Vesi(372) 62 62 200AttachmentTallinna Vesi- PIE kons 2024 est

Continue reading

NEO Battery Materials Appoints Dr. Matthew Dawson, CEO of Elementium Materials, as Senior Scientific Advisor

TORONTO, May 02, 2025 (GLOBE NEWSWIRE) — NEO Battery Materials Ltd. (“NEO” or the “Company”) (TSXV: NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to announce the appointment of Dr. Matthew Dawson, Founder and Chief Executive Officer of Elementium Materials Inc., to the Company’s Scientific Advisory Board. Earning his Ph.D. in Mechanical Engineering from the Massachusetts Institute of Technology (MIT), Dr. Dawson is a seasoned global executive, technology founder, and investor with nearly two decades of experience in developing and commercializing next-generation energy transition technologies. Across his professional career, he has served as CEO, CTO, and Investment Director at emerging technology companies and has founded several successful...

Continue reading

ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium

Vagal Neuromodulation Offers a Novel Approach to Treating Diabetes and Hypoglycemia Device Demonstrates the Ability to Modulate Glucose Levels Without Cardiac Side Effects, Overcoming a Key Limitation Of Conventional Vagal Stimulation Techniques IRVINE, Calif., May 02, 2025 (GLOBE NEWSWIRE) — ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will present pre-clinical data on its proprietary Diabetes Neuromodulation device in a poster presentation at the 12th Annual Minnesota Neuromodulation Symposium, being held in Minneapolis. Poster Presentation Details:Poster Title: Stimulation of the Posterior Sub-Diaphragmatic Vagal Trunk Reverses Insulin-Induced Severe Hypoglycemia in a Swine Model of Type 1 Diabetes Mellitus Poster Number: 3308 Author:...

Continue reading

electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies

Addition of Quell® Platform Broadens electroCore’s Bioelectronic Technology Portfolio and Accelerates Growth in Chronic Pain and Wellness Markets ROCKAWAY, N.J., May 02, 2025 (GLOBE NEWSWIRE) — electroCore, Inc. (“ECOR,” “electroCore,” or the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic technology company, announced today the completion of the merger (the “Merger”) with NeuroMetrix, Inc. (“NeuroMetrix” or “NURO”) (Nasdaq: NURO), positioning itself as a diversified leader in non-invasive health and wellness solutions. The acquisition of NeuroMetrix’s Quell® Fibromyalgia Solution expands electroCore’s portfolio of non-invasive bioelectronic therapies, strengthens its commercial reach — particularly within the VA Hospital System — and is expected to meaningfully increase its addressable market for the treatment of chronic...

Continue reading

iBio Reports Fiscal Third Quarter 2025 Financial Results

SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) — iBio, Inc. (Nasdaq:IBIO), today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress. “During the third quarter we were able to broaden our access to investors given our move to Nasdaq and subsequently in April, strengthened our financial position with a $6.2 million warrant-inducement equity raise, positioning us for continued growth and keeping us on track for regulatory submission of IBIO-600 in 2026,” said Martin Brenner, Ph.D., DVM, iBio’s Chief Executive Officer and Chief Scientific Officer. “At the same time, we made significant strides in our pipeline, with promising non-human primate data for IBIO-600 and the in-licensing of a first-in-class Activin E antibody, two antibodies we truly believe are bringing us closer...

Continue reading

Marex Group plc Announces Pricing of U.S.$500 Million Senior Notes Offering

NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) — Marex Group plc (Nasdaq: MRX) (“Marex”), the diversified global financial services platform, announced the pricing on May 1, 2025 of a public offering (the “Offering”) of U.S.$500 million aggregate principal amount of its 5.829% Senior Notes due 2028 (the “Notes”). The Notes will be issued at a price to the public equal to 100.000% of the principal amount thereof and will be senior unsecured obligations of Marex. The Offering is expected to close on or about May 8, 2025, subject to the satisfaction of customary closing conditions. Marex intends to use the net proceeds from the Offering for working capital, to fund incremental growth and for other general corporate purposes. Ian Lowitt, CEO of Marex, commented: “This successful debt issuance further diversifies our sources of funding and...

Continue reading

Form 8.3 – [TRAKM8 HOLDINGS PLC – Opening Disclosure – 01 05 2025] – (CGAML)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree TRAKM8 HOLDINGS PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

Form 8.3 – [GLOBALDATA PLC – 01 05 2025] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree GLOBALDATA PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.